Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?
作者信息
Gérard Alexandre O, Laurain Audrey, Favre Guillaume, Drici Milou-Daniel, Esnault Vincent L M
机构信息
Nephrology-Dialysis-Transplantation Department, Pasteur Hospital, Université Côte d'Azur, Nice, France.
Pharmacology Department, Pasteur Hospital, Université Côte d'Azur, Nice, France.
出版信息
Diabetes Care. 2022 Oct 1;45(10):e148-e149. doi: 10.2337/dc22-0921.
Abstract
摘要
相似文献
1
Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?SGLT2抑制剂对2型糖尿病合并晚期慢性肾脏病患者肾小管-肾小球反馈的激活作用：是神话的终结？
Diabetes Care. 2022 Oct 1;45(10):e148-e149. doi: 10.2337/dc22-0921.
2
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.钠-葡萄糖协同转运蛋白抑制剂的肾脏作用。
Am J Cardiol. 2019 Dec 15;124 Suppl 1(Suppl 1):S28-S35. doi: 10.1016/j.amjcard.2019.10.027.
3
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.SGLT2 抑制剂对肾脏的保护作用：在急性和慢性肾脏病中的作用。
Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3.
4
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.钠-葡萄糖共转运蛋白 2 抑制剂降低平均动脉压可改善合并慢性肾脏病的 2 型糖尿病患者的肾脏复合结局：日本倾向评分匹配模型分析。
J Diabetes Investig. 2021 Aug;12(8):1408-1416. doi: 10.1111/jdi.13491. Epub 2021 Feb 1.
5
SGLT2 Inhibitors and the Diabetic Kidney.钠-葡萄糖协同转运蛋白 2 抑制剂与糖尿病肾脏疾病
Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.
6
Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors.与胱抑素 C 相比，2 型糖尿病患者接受钠-葡萄糖共转运蛋白 2 抑制剂治疗时，基于肌酐计算的肾小球滤过率被高估。
Diabet Med. 2022 Jan;39(1):e14659. doi: 10.1111/dme.14659. Epub 2021 Aug 2.
7
Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?我们是否有足够的证据支持在晚期肾病患者中使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂来降低主要不良心血管事件（MACE）的发生风险？
Eur J Intern Med. 2019 Dec;70:e25-e26. doi: 10.1016/j.ejim.2019.10.014. Epub 2019 Nov 1.
8
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.SGLT2 抑制剂在 2 型糖尿病合并慢性肾脏病患者中的疗效和肾脏结局。
Postgrad Med. 2019 Jan;131(1):31-42. doi: 10.1080/00325481.2019.1549459. Epub 2018 Nov 30.
9
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.SGLT2 抑制剂的肾脏和心血管保护机制评估：基于模型的临床数据分析。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.
10
Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.钠-葡萄糖共转运蛋白 2 抑制剂的急性肾结局：真实世界数据分析。
Diabetes Obes Metab. 2019 Feb;21(2):340-348. doi: 10.1111/dom.13532. Epub 2018 Oct 15.
引用本文的文献
1
Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.钠-葡萄糖协同转运蛋白2抑制剂在非糖尿病慢性肾脏病中的应用：作用机制、疗效及安全性
Front Med (Lausanne). 2025 Jul 1;12:1574693. doi: 10.3389/fmed.2025.1574693. eCollection 2025.
2
Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system.口服抗糖尿病药物对肾素-血管紧张素-醛固酮系统的影响。
Eur J Clin Pharmacol. 2025 Jun;81(6):801-813. doi: 10.1007/s00228-025-03830-w. Epub 2025 Apr 1.
3
Cardiorenal Disease and Heart Failure with Preserved Ejection Fraction: Two Sides of the Same Coin.心肾疾病与射血分数保留的心力衰竭：同一枚硬币的两面。
Cardiorenal Med. 2025;15(1):108-121. doi: 10.1159/000543390. Epub 2025 Jan 8.
4
Cardio-renal protective effect and safety of sodium-glucose cotransporter 2 inhibitors for chronic kidney disease patients with eGFR < 60 mL/min/1.73 m2: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂对 eGFR<60mL/min/1.73m2 的慢性肾脏病患者的心肾保护作用和安全性：系统评价和荟萃分析。
BMC Nephrol. 2024 Nov 1;25(1):392. doi: 10.1186/s12882-024-03833-2.
5
Resting-state MRI reveals spontaneous physiological fluctuations in the kidney and tracks diabetic nephropathy in rats.静息态 MRI 揭示了肾脏的自发生理波动，并可追踪大鼠的糖尿病肾病。
Am J Physiol Renal Physiol. 2024 Jul 1;327(1):F113-F127. doi: 10.1152/ajprenal.00423.2023. Epub 2024 Apr 25.
6
Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus.2型糖尿病患者的空腹胰高血糖素样肽-1水平与蛋白尿呈负相关。
J Pers Med. 2024 Mar 1;14(3):280. doi: 10.3390/jpm14030280.
7
SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease.SGLT2 抑制通过肾素谱系细胞促进实验性肾病中的肾小球再殖。
Acta Physiol (Oxf). 2024 Mar;240(3):e14108. doi: 10.1111/apha.14108. Epub 2024 Feb 5.
8
The cardio-renal-metabolic connection: a review of the evidence.心肾代谢关联：证据回顾。
Cardiovasc Diabetol. 2023 Jul 31;22(1):195. doi: 10.1186/s12933-023-01937-x.
9
Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂对晚期慢性肾脏病患者肾脏、心血管和安全性结局的影响：一项随机对照试验的系统评价和荟萃分析。
Acta Diabetol. 2023 Mar;60(3):325-335. doi: 10.1007/s00592-022-01989-7. Epub 2022 Nov 1.
10
New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review.糖尿病患者容量控制的新策略：一项叙述性综述
Pharmaceutics. 2022 Jul 28;14(8):1569. doi: 10.3390/pharmaceutics14081569.
本文引用的文献
1
Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy.肾性糖尿中的球管反馈：模拟长期钠-葡萄糖协同转运蛋白2抑制剂治疗
Kidney Med. 2019 Dec 4;2(1):76-79. doi: 10.1016/j.xkme.2019.09.006. eCollection 2020 Jan-Feb.
2
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.在 RED 随机、双盲试验中，二甲双胍治疗的 2 型糖尿病患者中，SGLT2 抑制剂达格列净的肾脏血流动力学效应是由肾小球后血管舒张引起的，而不是由肾小球前血管收缩引起的。
Kidney Int. 2020 Jan;97(1):202-212. doi: 10.1016/j.kint.2019.09.013. Epub 2019 Oct 10.
3
Nephrosclerosis: update on a centenarian.肾硬化症：一位百岁老人的最新情况
Nephrol Dial Transplant. 2015 Nov;30(11):1833-41. doi: 10.1093/ndt/gfu366. Epub 2014 Dec 8.
4
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.1 型糖尿病患者钠-葡萄糖共转运蛋白 2 抑制剂的肾脏血流动力学效应。
Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.
5
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.与联合使用 ACEI+ARB 全剂量滴定相比，使用半剂量 ACEI+ARB 联合滴定可更好地降低蛋白尿。
Nephrol Dial Transplant. 2010 Jul;25(7):2218-24. doi: 10.1093/ndt/gfp776. Epub 2010 Jan 26.
Zotero 插件